This title appears in the Scientific Report :
2021
Please use the identifier:
http://hdl.handle.net/2128/30108 in citations.
Please use the identifier: http://dx.doi.org/10.3390/cancers13236030 in citations.
Evaluation of 3-l- and 3-d-[18F]Fluorophenylalanines as PET Tracers for Tumor Imaging
Evaluation of 3-l- and 3-d-[18F]Fluorophenylalanines as PET Tracers for Tumor Imaging
Purpose: The preclinical evaluation of 3-l- and 3-d-[18F]FPhe in comparison to [18F]FET, an established tracer for tumor imaging. Methods: In vitro studies were conducted with MCF-7, PC-3, and U87 MG human tumor cell lines. In vivo µPET studies were conducted in healthy rats with/without the inhibit...
Saved in:
Personal Name(s): | Krämer, Felicia |
---|---|
Gröner, Benedikt / Hoffmann, Chris / Craig, Austin / Brugger, Melanie / Drzezga, Alexander / Timmer, Marco / Neumaier, Felix / Zlatopolskiy, Boris D. / Endepols, Heike / Neumaier, Bernd (Corresponding author) | |
Contributing Institute: |
Molekulare Organisation des Gehirns; INM-2 Nuklearchemie; INM-5 |
Published in: | Cancers, 13 (2021) 23, S. 6030 - |
Imprint: |
Basel
MDPI
2021
|
DOI: |
10.3390/cancers13236030 |
Document Type: |
Journal Article |
Research Program: |
Neuroimaging |
Link: |
OpenAccess |
Publikationsportal JuSER |
Please use the identifier: http://dx.doi.org/10.3390/cancers13236030 in citations.
LEADER | 07219nam a2201057 a 4500 | ||
---|---|---|---|
001 | 903019 | ||
005 | 20240308203405.0 | ||
024 | 7 | |a 10.3390/cancers13236030 |2 doi | |
024 | 7 | |a 2128/30108 |2 Handle | |
024 | 7 | |a 34885141 |2 pmid | |
024 | 7 | |a WOS:000734552300001 |2 WOS | |
037 | |a FZJ-2021-04748 | ||
082 | |a 610 | ||
100 | 1 | |a Krämer, Felicia |0 P:(DE-Juel1)186984 |b 0 | |
245 | |a Evaluation of 3-l- and 3-d-[18F]Fluorophenylalanines as PET Tracers for Tumor Imaging | ||
260 | |a Basel |c 2021 |b MDPI | ||
520 | |a Purpose: The preclinical evaluation of 3-l- and 3-d-[18F]FPhe in comparison to [18F]FET, an established tracer for tumor imaging. Methods: In vitro studies were conducted with MCF-7, PC-3, and U87 MG human tumor cell lines. In vivo µPET studies were conducted in healthy rats with/without the inhibition of peripheral aromatic l-amino acid decarboxylase by benserazide pretreatment (n = 3 each), in mice bearing subcutaneous MCF-7 or PC-3 tumor xenografts (n = 10), and in rats bearing orthotopic U87 MG tumor xenografts (n = 14). Tracer accumulation was quantified by SUVmax, SUVmean and tumor-to-brain ratios (TBrR). Results: The uptake of 3-l-[18F]FPhe in MCF-7 and PC-3 cells was significantly higher relative to [18F]FET. The uptake of all three tracers was significantly reduced by the suppression of amino acid transport systems L or ASC. 3-l-[18F]FPhe but not 3-d-[18F]FPhe exhibited protein incorporation. In benserazide-treated healthy rats, brain uptake after 42–120 min was significantly higher for 3-d-[18F]FPhe vs. 3-l-[18F]FPhe. [18F]FET showed significantly higher uptake into subcutaneous MCF-7 tumors (52–60 min p.i.), while early uptake into orthotopic U87 MG tumors was significantly higher for 3-l-[18F]FPhe (SUVmax: 3-l-[18F]FPhe, 107.6 ± 11.3; 3-d-[18F]FPhe, 86.0 ± 4.3; [18F]FET, 90.2 ± 7.7). Increased tumoral expression of LAT1 and ASCT2 was confirmed immunohistologically. Conclusion: Both novel tracers enable accurate tumor delineation with an imaging quality comparable to [18F]FET. | ||
588 | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de | ||
700 | 1 | |a Gröner, Benedikt |0 P:(DE-Juel1)180812 |b 1 |u fzj | |
700 | 1 | |a Hoffmann, Chris |0 P:(DE-Juel1)180770 |b 2 |u fzj | |
700 | 1 | |a Craig, Austin |0 P:(DE-Juel1)176281 |b 3 | |
700 | 1 | |a Brugger, Melanie |0 P:(DE-Juel1)131826 |b 4 | |
700 | 1 | |a Drzezga, Alexander |0 P:(DE-Juel1)177611 |b 5 | |
700 | 1 | |a Timmer, Marco |0 P:(DE-HGF)0 |b 6 | |
700 | 1 | |a Neumaier, Felix |0 P:(DE-Juel1)175142 |b 7 | |
700 | 1 | |a Zlatopolskiy, Boris D. |0 P:(DE-Juel1)176188 |b 8 | |
700 | 1 | |a Endepols, Heike |0 P:(DE-Juel1)180330 |b 9 | |
700 | 1 | |a Neumaier, Bernd |0 P:(DE-Juel1)166419 |b 10 |e Corresponding author | |
773 | |a 10.3390/cancers13236030 |g Vol. 13, no. 23, p. 6030 - |0 PERI:(DE-600)2527080-1 |n 23 |p 6030 - |t Cancers |v 13 |y 2021 |x 2072-6694 | ||
856 | 4 | |u http://juser.fz-juelich.de/record/903019/files/cancers-13-06030.pdf |y OpenAccess | |
909 | C | O | |o oai:juser.fz-juelich.de:903019 |p openaire |p open_access |p OpenAPC |p driver |p VDB |p openCost |p dnbdelivery |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)180812 | |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)180770 | |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)131826 | |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)177611 | |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 7 |6 P:(DE-Juel1)175142 | |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 9 |6 P:(DE-Juel1)180330 | |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 10 |6 P:(DE-Juel1)166419 | |
913 | 1 | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 0 | |
914 | 1 | |y 2021 | |
915 | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-05-04 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-05-04 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-05-04 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-05-04 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-05-04 | ||
915 | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCERS : 2019 |d 2021-05-04 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2021-05-04 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2021-05-04 | ||
915 | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-05-04 | ||
915 | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2021-05-04 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-05-04 | ||
915 | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC | ||
915 | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID | ||
915 | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-05-04 | ||
915 | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-05-04 | ||
915 | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CANCERS : 2019 |d 2021-05-04 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-05-04 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2021-05-04 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-05-04 | ||
915 | p | c | |a APC keys set |2 APC |0 PC:(DE-HGF)0000 |
915 | p | c | |a Local Funding |2 APC |0 PC:(DE-HGF)0001 |
915 | p | c | |a DFG OA Publikationskosten |2 APC |0 PC:(DE-HGF)0002 |
915 | p | c | |a DOAJ Journal |2 APC |0 PC:(DE-HGF)0003 |
980 | 1 | |a FullTexts | |
980 | |a journal | ||
980 | |a VDB | ||
980 | |a UNRESTRICTED | ||
980 | |a I:(DE-Juel1)INM-5-20090406 | ||
980 | |a I:(DE-Juel1)INM-2-20090406 | ||
980 | |a APC | ||
536 | |a Neuroimaging |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 0 | ||
336 | |a ARTICLE |2 BibTeX | ||
336 | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1641912344_25030 |2 PUB:(DE-HGF) | ||
336 | |a Output Types/Journal article |2 DataCite | ||
336 | |a article |2 DRIVER | ||
336 | |a Nanopartikel unedler Metalle (Mg0, Al0, Gd0, Sm0) |0 0 |2 EndNote | ||
336 | |a JOURNAL_ARTICLE |2 ORCID | ||
920 | |l yes | ||
920 | |k Molekulare Organisation des Gehirns; INM-2 |0 I:(DE-Juel1)INM-2-20090406 |l Molekulare Organisation des Gehirns |x 1 | ||
920 | |k Nuklearchemie; INM-5 |0 I:(DE-Juel1)INM-5-20090406 |l Nuklearchemie |x 0 | ||
991 | |a Endepols, Heike |0 P:(DE-Juel1)180330 |b 9 | ||
991 | |a Zlatopolskiy, Boris |0 P:(DE-Juel1)176188 |b 8 | ||
991 | |a Neumaier, Felix |0 P:(DE-Juel1)175142 |b 7 | ||
991 | |a Timmer, Marco |0 P:(DE-HGF)0 |b 6 | ||
990 | |a Krämer, Maximiliane-Felicia |0 P:(DE-Juel1)186984 |b 0 | ||
991 | |a Drzezga, Alexander |0 P:(DE-Juel1)177611 |b 5 | ||
991 | |a Neumaier, Bernd |0 P:(DE-Juel1)166419 |b 10 |e Corresponding author | ||
991 | |a Brugger, Melanie |0 P:(DE-Juel1)131826 |b 4 | ||
991 | |a Craig, Austin |0 P:(DE-Juel1)176281 |b 3 | ||
991 | |a Hoffmann, Chris |0 P:(DE-Juel1)180770 |b 2 |u fzj | ||
991 | |a Gröner, Benedikt |0 P:(DE-Juel1)180812 |b 1 |u fzj |